No, ADC Therapeutics does not distribute cash dividends to its common shareholders. As a commercial-stage biotechnology company that continues to record net operating losses while investing heavily into research, clinical trials, and commercial expansion pipeline initiatives, the firm retains all available capital to fund ongoing drug development, support operational growth, and strengthen its balance sheet rather than issuing recurring dividend payouts.